Cancer Res Treat.  2020 Apr;52(2):335-350. 10.4143/crt.2020.206.

Cancer Statistics in Korea: Incidence, Mortality, Survival, andPrevalence in 2017

• Hong S
• Won YJ
• Park YR
• Jung KW
• Kong HJ
• Lee ES
• The Community of Population-Based
• Regional Cancer Registries

• KMID: 2500319
• DOI: http://doi.org/10.4143/crt.2020.206

Abstract

Purpose
This study reports the cancer statistics and temporal trends in Korea on a nationwide scale, including incidence, survival, prevalence, and mortality in 2017.
Materials and Methods
The incidence, survival, and prevalence rates of cancer were evaluated using data from the Korea National Cancer Incidence Database from 1999 to 2017 with follow-up until December 31, 2018. Deaths from cancer were assessed using cause-of-death data from 1983 to 2017, obtained from Statistics Korea. Crude and age-standardized rates (ASRs) for incidence, mortality, and prevalence, and 5-year relative survival rates were calculated and trend analysis was performed.
Results
In 2017, newly diagnosed cancer cases and deaths from cancer numbered 232,255 (ASR, 264.4 per 100,000) and 78,863 (ASR, 76.6 per 100,000), respectively. The overall cancer incidence rates increased annually by 3.5% from 1999 to 2011 and decreased by 2.7% annually thereafter. Cancer mortality rates have been decreasing since 2002, by 2.8% annually. The 5-year relative survival rate for all patients diagnosed with cancer between 2013 and 2017 was 70.4%, which contributed to a prevalence of approximately 1.87 million cases by the end of 2017.
Conclusion
The burden of cancer measured by incidence and mortality rates have improved in Korea, with the exception of a few particular cancers that are associated with increasing incidence or mortality rates. However, cancer prevalence is increasing rapidly, with the dramatic improvement in survival during the past several years. Comprehensive cancer control strategies and efforts should continue, based on the changes of cancer statistics.

Keyword

Incidence; Survival; Prevalence; Mortality; Neoplasms; Korea

Figure

• 

  Fig. 1. The five common sites of cancer incidence by age group and sex for 2017 in Korea. (A) Men. (B) Women. Numbers on each section are age-specific incidence rates per 100,000. CNS, central nervous system. a)Includes the gallbladder and other/unspecified parts of the biliary tract.

• 

  Fig. 2. Age-specific incidence rates of common cancers for 2017 in Korea. (A) Men. (B) Women.

• 

  Fig. 3. Annual age-standardized cancer incidence and mortality rates by sex for all sites from 1983 to 2017 in Korea. Age standardization was based on Segi’s world standard population.

• 

  Fig. 4. Trends in age-standardized incidences of selected cancers by sex from 1999 to 2017 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.

• 

  Fig. 5. Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2017 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population. a)Cancers of cervix uteri, corpus uteri, and unspecified parts of the uterus were combined (C53-C55), due to their unclear classifications in the past.

• 

  Fig. 6. Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2013-2017. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results (SEER) stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.

• 

  Fig. 7. Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2018 among all cancer patients diagnosed between 1999 and 2017.

Reference

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.

2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392:1789–858.

3. Jung KW, Won YJ, Kong HJ, Lee ES. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat. 2019; 51:417–30.

4. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001: first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–31.

5. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi. 1998; 45:1011–7.

6. Statistics Korea [Internet]. Daejeon: Statistics Korea;2018. [cited 2020 Feb 28]. Available from: http://kosis.kr.

7. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. 1st rev. Geneva: World Health Organization;2013.

8. World Health Organization. International statistical classification of diseases and related health problems, 10th rev. Geneva: World Health Organization;1994.

9. Cancer incidence in five continents. Vol. XI. Chapter 3. Classification and coding [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2020 Feb 28]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter3.aspx.

10. Young JL Jr, Roffers SD, Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual 2000: codes and coding instructions, National Cancer Institute, NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute;2001.

11. Cancer incidence in five continents. Vol. XI. Chapter 7. Age standardization [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2020 Feb 28]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter7.aspx.

12. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine;1960.

13. Surveillance Research Program. Joinpoint Regression Program, version 4.7.0.0 [Internet]. Bethesda, MD: National Cancer Institute;2019. [cited 2019 Dec 1]. Available from: https://surveillance.cancer.gov/joinpoint/.

14. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note, No. 10. Bethesda, MD: National Cancer Institute;1959.

15. Paul Dickman [Internet]. Stockholm: PaulDickman.com;2016. [cited 2020 Feb 28]. Available from: http://www.pauldickman.com.